3+ day, 7+ hour ago   (482+ words) What is the most compelling evidence supporting the use of nocturnal home hemodialysis—particularly for cardiovascular health, volume control, and quality of life? Nocturnal therapy is usually provided four to six times a night with average 5 or 6 to 10 hours for…...

2+ mon, 4+ week ago   (272+ words) Globally, glomerulonephritis (GN) is a leading cause of kidney damage and kidney failure. Previous studies have found a renoprotective benefit associated with finerenone in individuals with type 2 diabetes and in those with CKD without diabetes. However, few findings shed light…...

3+ mon, 2+ week ago   (167+ words) The analysis compared kidney function in patients who achieved CR by week 36 (CR36) or any time up to week 110 (CR110) with that in patients who did not achieve CR (non-CR), regardless of original treatment allocation. Compared with non-CR patients, CR110 patients were more…...

3+ mon, 2+ week ago   (369+ words) Bayer announced that the FDA has accepted and granted Priority Review to a Supplemental New Drug Application (sNDA) for finerenone for the treatment of adults with type 1 diabetes and chronic kidney disease. If approved for the investigational use, finerenone would…...

3+ mon, 2+ week ago   (330+ words) SURPASS-CVOT Trial Shows Tirzepatide Significantly Reduces Major Kidney Events Compared to Dulaglutide in Type 2 Diabetes A study published in The Lancet Diabetes & Endocrinology found that tirzepatide, a first-in-class dual agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP…...

3+ mon, 3+ week ago   (309+ words) The optimal treatment for kidney failure is kidney transplantation, resulting in improved survival and quality of life for patients and lower costs for healthcare systems. While short-term outcomes after transplantation have continuously improved, the long-term graft survival rate has plateaued,…...

3+ mon, 4+ week ago   (81+ words) Docwire News Research collaborators Mona Calvo, PhD, and nephrologist Jaime Uribarri, MD, speak with Joel Topf, MD, about renal nutrition and phosphate additives at the 2026 National Kidney Foundation (NKF) Spring Clinical Meetings. Dr. Calvo received the NKF’s Joel D. Kopple…...

4+ mon, 15+ hour ago   (61+ words) Docwire News Joel Topf, MD, interviews Shaunna Newton, MPH, of Spherix Global Insights at the 2026 National Kidney Foundation Spring Clinical Meetings about access to medications and home modalities in dialysis care. Access Issues in Dialysis Care Thoughts From the Incoming…...

4+ mon, 15+ hour ago   (84+ words) Docwire News Thoughts From the Incoming Editor of the American Journal of Kidney Diseases At the 2026 National Kidney Foundation Spring Clinical Meetings, Wolfgang C. Winkelmayer, MD, MPH, ScD, who will become editor-in-chief of the American Journal of Kidney Diseases in 2027, speaks…...

4+ mon, 4+ day ago   (166+ words) In the 26-week randomized controlled period of the phase 3 VALIANT trial, the C3/C3b inhibitor pegcetacoplan led to significant reductions in proteinuria among patients with immune complex membranoproliferative glomerulonephritis (IC-MPGN) when compared with placebo. In the following 26-week open-label period, all patients…...